HDAC9 and acute myeloid leukemia: While early preclinical studies demonstrated antineoplastic activity for HDAC inhibitors [102, 103] and hypomethylating agents [104] in AML1/ETO-expressing cells, the clinical use of HDAC inhibitors in AML has been disappointing to date [105–107].